TISIDB

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Secreted
Domain	PF07686 Immunoglobulin V-set domain
Function	Stimulates neutrophil and monocyte-mediated inflammatory responses. Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock.

> Gene Ontology [ TOP ]
Biological Process	GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0002367 cytokine production involved in immune response GO:0002374 cytokine secretion involved in immune response GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002446 neutrophil mediated immunity GO:0006959 humoral immune response GO:0009306 protein secretion GO:0030593 neutrophil chemotaxis GO:0030595 leukocyte chemotaxis GO:0031640 killing of cells of other organism GO:0035821 modification of morphology or physiology of other organism GO:0042107 cytokine metabolic process GO:0042742 defense response to bacterium GO:0044364 disruption of cells of other organism GO:0045123 cellular extravasation GO:0050663 cytokine secretion GO:0050755 chemokine metabolic process GO:0050829 defense response to Gram-negative bacterium GO:0050900 leukocyte migration GO:0051702 interaction with symbiont GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction GO:0051818 disruption of cells of other organism involved in symbiotic interaction GO:0051851 modification by host of symbiont morphology or physiology GO:0051852 disruption by host of symbiont cells GO:0051873 killing by host of symbiont cells GO:0051883 killing of cells in other organism involved in symbiotic interaction GO:0060326 cell chemotaxis GO:0070942 neutrophil mediated cytotoxicity GO:0070943 neutrophil mediated killing of symbiont cell GO:0070944 neutrophil mediated killing of bacterium GO:0070945 neutrophil mediated killing of gram-negative bacterium GO:0071621 granulocyte chemotaxis GO:0072672 neutrophil extravasation GO:0097529 myeloid leukocyte migration GO:0097530 granulocyte migration GO:0098542 defense response to other organism GO:1990266 neutrophil migration
Molecular Function	GO:0097110 scaffold protein binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-2172127: DAP12 interactions R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TREM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between TREM1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27568523	Leukemia	Inhibit immunity	Forced expression of the downregulated DNA repair genes, Rad51c or Trp53i13, in the Fanca-/-?pre-LSCs partially rescues DDR but has no effect on leukemia, whereas shRNA knockdown of the upregulated immune receptor genes Trem1 or Pilrb improves leukemia-related survival, but not DDR or genomic instability. Furthermore, Trem1 cooperates with diminished DDR in vivo to promote Fanca-/-?pre-LSC expansion and leukemia development.

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TREM1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TREM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.771	0.186
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.68	0.131
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.101	0.909
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.972	0.107
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.358	0.344
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.473	0.815
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.421	0.581
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.82	0.495
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.226	0.847
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.309	0.813
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.396	0.828
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.486	0.0624

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TREM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TREM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TREM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TREM1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TREM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TREM1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TREM1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TREM1
Name	triggering receptor expressed on myeloid cells 1
Aliases	TREM-1; CD354; triggering receptor expressed on monocytes 1; triggering-receptor TREM1; CD antigen CD354
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TREM1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting TREM1.

ID	Name	Drug Type	Targets	#Targets
DB01694	D-tartaric acid	Small Molecule	ATP6V1C1, B3GAT1, DDX6, HIF1AN, TREM1	5

Browse TREM1